Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study
Authors:
- 1 May 2009
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 160 (5) , 1075-1082
Abstract
Detailed information is lacking on effectiveness of methotrexate (MTX) in sclerotic skin diseases, side-effects, and duration of remission after discontinuation. To determine effectiveness, side-effects and period of remission gained by use of MTX in sclerotic skin diseases. All patients with a sclerotic skin disease who were treated with MTX (group A) or MTX with corticosteroids (CS) (group B) between 1995 and 2007 were evaluated. Detailed information was collected on dosage and duration of MTX treatment, concomitant immunosuppressive medication and CS treatment, effectiveness, side-effects, duration of the remission period, and time until restart. Fifty-eight patients (A, n = 47; B, n = 11) were evaluated. Clinical assessment revealed that 38 patients (81%) treated with MTX and 11 patients (100%) treated with MTX + CS showed improvement of sclerotic skin. After one treatment course 51% of the patients treated with MTX and 73% treated with MTX + CS reached remission status with a median follow-up time of 55 and 58 months. Patients showing relapse still responded to a second and even to a third course of MTX. Patients who showed a relapse had received a lower cumulative dose, due to a shorter period of treatment with MTX in the first course. Serious side-effects were seen in six patients (10%). MTX was an effective treatment for various sclerotic skin diseases with a long period of remission and relatively low toxicity. Patients showing relapse still responded to a second and third course of MTX.Keywords
This publication has 17 references indexed in Scilit:
- Ultraviolet A1 phototherapyBritish Journal of Dermatology, 2003
- Treatment of SclerodermaArchives of Dermatology, 2002
- Disseminated scleroderma of a Japanese patient successfully treated with bath PUVA photochemotherapyJournal of Cutaneous Medicine and Surgery, 2001
- Low-dose methotrexate in the treatment of widespread morpheaJournal of the American Academy of Dermatology, 1998
- Localized sclerodermaSeminars in Cutaneous Medicine and Surgery, 1998
- COMPARISON OF METHOTREXATE WITH PLACEBO IN THE TREATMENT OF SYSTEMIC SCLEROSIS: A 24 WEEK RANDOMIZED DOUBLE-BLIND TRIAL, FOLLOWED BY A 24 WEEK OBSERVATIONAL TRIALRheumatology, 1996
- EFFECT OF METHOTREXATE ALONE OR IN COMBINATION WITH SULPHASALAZINE ON THE PRODUCTION AND CIRCULATING CONCENTRATIONS OF CYTOKINES AND THEIR ANTAGONISTS. LONGITUDINAL EVALUATION IN PATIENTS WITH RHEUMATOID ARTHRITISRheumatology, 1995
- Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized sclerodermaArchives of Dermatological Research, 1995
- An investigation into the incidence of auto-immune disorders in patients with localized morphoeaBritish Journal of Dermatology, 1989
- The Pharmacology and Clinical Use of MethotrexateNew England Journal of Medicine, 1983